The application of antiviral and antimicrobial agents is growing in the novel era, along with the manufacturing of vaccines for the efficient control of viral diseases, which drives the growth of the market.
Antivirals and antimicrobial technology treat and prevent viral infections, with every antiviral created to manage only one particular virus. Antimicrobials show promising substitutes for addressing bacterial and viral multidrug resistance because of their distinctive characteristics. Antimicrobial polymers with nanosized materials are employed as antiviral coatings or sprays for regulatory viral load on contaminated surfaces. Antiviral drugs are a class of medication used to manage viral infections. Most antivirals target particular viruses. Progressive antimicrobial bandages and hydrogels release therapeutic agents to manage burns, diabetic ulcers, and surgical wounds. Antimicrobial laminates, paints, and metallic coatings are used in hospitals, schools, and public transit to lower fomite transmission of pathogens.
The global antiviral and antimicrobial technology market size was estimated at USD 16.84 billion in 2025 and is predicted to increase from USD 18.85 billion in 2026 to approximately USD 51.93 billion by 2035, expanding at a CAGR of 11.92% from 2026 to 2035.
More than 2.8 million antibiotic-resistant infections occur in the United States every year, accounting for 35,000 deaths.
Recent advances in host-targeting antiviral drugs show a therapeutic approach that curtails viral replication by interfering with specific host cell factors. Host cell kinases are significant in the replication of various viruses, making them promising targets for antiviral drug advancement. Host-directed therapies are an effective substitute for traditional antimicrobial approaches. HDTs target host-cell machinery significant for bacterial pathogenesis to manage bacterial infections alone or as adjunctive treatment with traditional antibiotics. HDTs for clinically significant pathogens identify formulation strategies that enhance their therapeutic effectiveness and provide insights toward further development of HDTs for bacterial infections.
By technology type, the antimicrobial technology segment contributed the largest U.S. antiviral and antimicrobial technology market share of 68% in 2025. Antimicrobial technology has transformed facility cleanliness and is a significant aid in the fight against damaging and product-damaging microbes. Antimicrobial technology plays a noteworthy role in inhibiting the growth of degrading microbes in various environments, from hospital surroundings to public transport.
By material type, the coatings & surface treatments segment contributed the largest market share of 34%, and antiviral surface coatings lower the reliance on outdated disinfectants. These surfaces continue to be actively antimicrobial between periods of active cleaning of the surfaces, enabling a much more limited and optimized application of disinfectants. Antimicrobial coatings disinfect incessantly as long as the coating remains intact on the surface.
By application, the healthcare segment held a dominant share of 29% in the U.S. antiviral and antimicrobial technology market, as antiviral and antimicrobial technology supports reducing patient and staff exposure to different bacteria and viruses and reduces the risk for a healthcare-associated infection. Antivirals manage viruses and prevent them from spreading. They are efficient against flu, herpes, HIV, and other contagious viral infections. These drugs ease symptoms and limit the length of a viral infection.
By end user, the hospitals & clinics segment contributed the largest market share of 31%, as antiviral and antimicrobial technology improves patients' health, supporting quick-healing wounds to heal, and averting secondary infections, enhancing the quality of life for patients and lowering the strain on medical care systems. Antivirals manage viruses and prevent them from spreading. They're efficient against flu, herpes, HIV, and other contagious viral infections.
The four organizations in this market dominate the U.S. antiviral and antimicrobial technology market. Meanwhile, Pfizer Inc., the organization, runs advanced antimicrobial testing databases such as ATLAS to monitor and combat antimicrobial resistance (AMR). Gilead Sciences, Inc., a leading biopharmaceutical company renowned for its virology portfolio, is heavily focused on HIV/AIDS. AbbVie Inc., this company offers novel beta-lactamase inhibitor combination therapies that tackle tricky, drug-resistant bacteria in the medical care setting. Vertex Pharmaceuticals, a biopharma innovator significant spending in next-generation research and specialized viral alleviation medications.
By Technology Type
By Material Type
By Application
By End User
By Deployment Form
By Distribution Channel
